3,4-Methylenedioxymethamphetamine (Ecstasy) Activates Skeletal Muscle Nicotinic Acetylcholine Receptors
Authors:
- James J. A. HeffronJHJames J. A. Heffron
- Karin Jurkat-RottKJKarin Jurkat-Rott
- Grainne O’sUllivanGOGrainne O’sUllivan
- Andreas AltAAAndreas Alt
- Friedrich SchlesingerFSFriedrich Schlesinger
- Johannes BuflerJBJohannes Bufler
- Frank Lehmann-HornFLFrank Lehmann-Horn
- 1 September 2005
- journal article
- Published by Elsevier in The Journal of Pharmacology and Experimental Therapeutics
- Vol. 314 (3) , 1267-1273
Abstract
Adverse 3,4-methylenedioxymethamphetamine (MDMA; ecstasy) effects are usually ascribed to neurotransmitter release in the central nervous system. Since clinical features such as fasciculations, muscle cramps, rapidly progressing hyperthermia, hyperkalemia, and rhabdomyolysis point to the skeletal muscle as additional target, we studied the effects of MDMA on native and cultured skeletal muscle. We addressed the question whether malignant hyperthermia (MH)-susceptible (MHS) muscle is predisposed to adverse MDMA reactions. Force measurements on muscle strips showed that 100 μM MDMA, a concentration close to that determined in some MDMA users, regularly enhanced the sensitivity of skeletal muscle to caffeine-induced contractures but did not cause contractures on its own. The left-shift of the dose-response curve induced by MDMA was greater in normal than in MHS muscle. Furthermore, MDMA did not release Ca2+ from isolated sarcoplasmic reticulum vesicles. These findings do not support the view of an MH-triggering effect on muscle. However, MDMA induced Ca2+ transients in myotubes and increased their acidification rate. Surprisingly, α-bungarotoxin, a specific antagonist of the nicotinic acetylcholine receptor (nAChR), abolished these MDMA effects. The nAChR agonistic action of MDMA was confirmed by patch-clamp measurements of ion currents on human embryonic kidney cells expressing nAChR. We conclude that the neuromuscular junction is a target of MDMA and that an activation of nAChR contributes to the muscle-related symptoms of MDMA users. The drug may be of particular risk in individuals with abundant extrajunctional nAChR such as in generalized denervation or muscle regeneration processes and may act on central nAChR.Keywords
This publication has 42 references indexed in Scilit:
- The Role of Mitochondrial Uncoupling in 3,4-Methylenedioxymethamphetamine-Mediated Skeletal Muscle Hyperthermia and RhabdomyolysisThe Journal of Pharmacology and Experimental Therapeutics, 2005
- Complications of anaesthesia in neuromuscular disordersNeuromuscular Disorders, 2005
- Induction of Malignant Hyperthermia in Susceptible Swine by 3,4-Methylenedioxymethamphetamine (“Ecstasy”)Anesthesiology, 2003
- Analgesic effect of intrathecally administered orexin‐A in the rat formalin test and in the rat hot plate testBritish Journal of Pharmacology, 2002
- Effects of HMG-CoA Reductase Inhibitors on Skeletal MuscleDrug Safety, 2002
- An unusual case of Ecstasy poisoningIntensive Care Medicine, 1996
- Pharmacokinetics of Succinylcholine in Man.The Tohoku Journal of Experimental Medicine, 1993
- Tight Mask Fit Could Have Prevented “Airway” ObstructionAnesthesiology, 1992
- Voluntary activation and fiber density of fasciculations in motor neuron diseaseAnnals of Neurology, 1992
- In vitro diagnosis of susceptibility to malignant hyperthermia: evaluation of tests with halothane‐caffeine, potassium chloride, suxamethonium and caffeine‐suxamethoniumActa Anaesthesiologica Scandinavica, 1987